Loading...

Aurinia Pharmaceuticals

DB:IKAP
Snowflake Description

Flawless balance sheet with exceptional growth potential.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
IKAP
DB
CA$775M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Aurinia Pharmaceuticals Inc., a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutic drugs for the treatment of various diseases in the United States and China. The last earnings update was 37 days ago. More info.


Add to Portfolio Compare Print
IKAP Share Price and Events
7 Day Returns
-0.7%
DB:IKAP
0.4%
DE Biotechs
0.8%
DE Market
1 Year Returns
28.9%
DB:IKAP
-5.6%
DE Biotechs
-4.5%
DE Market
IKAP Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Aurinia Pharmaceuticals (IKAP) -0.7% -4.2% 0.9% 28.9% 124.1% 124.7%
DE Biotechs 0.4% 7.3% -6.5% -5.6% 51.9% 10.5%
DE Market 0.8% 6.9% 8.1% -4.5% 10.4% 13.9%
1 Year Return vs Industry and Market
  • IKAP outperformed the Biotechs industry which returned -5.6% over the past year.
  • IKAP outperformed the Market in Germany which returned -4.5% over the past year.
Price Volatility
IKAP
Industry
5yr Volatility vs Market

IKAP Value

 Is Aurinia Pharmaceuticals undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Aurinia Pharmaceuticals to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Aurinia Pharmaceuticals.

DB:IKAP Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 4 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 8%
Perpetual Growth Rate 10-Year DE Government Bond Rate 0.2%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for DB:IKAP
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year DE Govt Bond Rate 0.2%
Equity Risk Premium S&P Global 6%
Biotechs Unlevered Beta Simply Wall St/ S&P Global 1.45
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 1.453 (1 + (1- 26.5%) (0%))
1.303
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.3
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 0.23% + (1.303 * 5.96%)
8%

Discounted Cash Flow Calculation for DB:IKAP using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Aurinia Pharmaceuticals is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

DB:IKAP DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (USD, Millions) Source Present Value
Discounted (@ 8%)
2019 -86.00 Analyst x1 -79.63
2020 -111.00 Analyst x1 -95.17
2021 -61.00 Analyst x1 -48.43
2022 -3.00 Analyst x1 -2.21
2023 111.00 Analyst x1 75.56
2024 189.81 Est @ 71% 119.63
2025 284.27 Est @ 49.77% 165.90
2026 383.49 Est @ 34.9% 207.24
2027 477.45 Est @ 24.5% 238.91
2028 559.66 Est @ 17.22% 259.32
Present value of next 10 years cash flows $841.13
DB:IKAP DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2028 × (1 + g) ÷ (Discount Rate – g)
= $559.66 × (1 + 0.23%) ÷ (8% – 0.23%)
$7,220.68
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= $7,220.68 ÷ (1 + 8%)10
$3,345.66
DB:IKAP Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= $841.13 + $3,345.66
$4,186.79
Equity Value per Share
(USD)
= Total value / Shares Outstanding
= $4,186.79 / 91.64
$69.15
DB:IKAP Discount to Share Price
Calculation Result
Exchange Rate USD/CAD
(Reporting currency to currency of TSX:AUP)
1.349
Value per Share
(CAD)
= Value per Share in USD x Exchange Rate (USD/CAD)
= $45.69 x 1.349
CA$61.65
Non-primary Listing Adjustment Factor 1 share in DB:IKAP represents 0.66072x of TSX:AUP
(This could be a different class, a depositary receipt, a different currency, or all of these things.)
0.66072x
Value per Share
(Listing Adjusted, EUR)
= Value per Share (CAD) x Listing Adjustment Factor
= CA$ 61.65 x 0.66072
€40.74
Value per share (EUR) From above. €40.74
Current discount Discount to share price of €5.52
= -1 x (€5.52 - €40.74) / €40.74
86.5%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price Aurinia Pharmaceuticals is available for.
Intrinsic value
>50%
Share price is €5.52 vs Future cash flow value of €40.74
Current Discount Checks
For Aurinia Pharmaceuticals to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • Aurinia Pharmaceuticals's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • Aurinia Pharmaceuticals's share price is below the future cash flow value, and at a substantial discount (> 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Aurinia Pharmaceuticals's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Aurinia Pharmaceuticals's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:IKAP PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in USD $-0.76
TSX:AUP Share Price ** TSX (2019-04-25) in CAD CA$8.35
TSX:AUP Share Price converted to USD reporting currency Exchange rate (CAD/ USD) 0.741 $6.19
Europe Biotechs Industry PE Ratio Median Figure of 30 Publicly-Listed Biotechs Companies 22.58x
Germany Market PE Ratio Median Figure of 424 Publicly-Listed Companies 20.1x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Aurinia Pharmaceuticals.

DB:IKAP PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= TSX:AUP Share Price ÷ EPS (both in USD)

= 6.19 ÷ -0.76

-8.18x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Aurinia Pharmaceuticals is loss making, we can't compare its value to the Europe Biotechs industry average.
  • Aurinia Pharmaceuticals is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Aurinia Pharmaceuticals's expected growth come at a high price?
Raw Data
DB:IKAP PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -8.18x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 4 Analysts
63.5%per year
Europe Biotechs Industry PEG Ratio Median Figure of 22 Publicly-Listed Biotechs Companies 1.33x
Germany Market PEG Ratio Median Figure of 268 Publicly-Listed Companies 1.57x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Aurinia Pharmaceuticals, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Aurinia Pharmaceuticals's assets?
Raw Data
DB:IKAP PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in USD $1.32
TSX:AUP Share Price * TSX (2019-04-25) in CAD CA$8.35
TSX:AUP Share Price converted to USD reporting currency Exchange rate (CAD/ USD) 0.741 $6.19
Germany Biotechs Industry PB Ratio Median Figure of 15 Publicly-Listed Biotechs Companies 3.83x
Germany Market PB Ratio Median Figure of 574 Publicly-Listed Companies 1.87x
DB:IKAP PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= TSX:AUP Share Price ÷ Book Value per Share (both in USD)

= 6.19 ÷ 1.32

4.7x

* Primary Listing of Aurinia Pharmaceuticals.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Aurinia Pharmaceuticals is overvalued based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess Aurinia Pharmaceuticals's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Aurinia Pharmaceuticals has a total score of 2/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

IKAP Future Performance

 How is Aurinia Pharmaceuticals expected to perform in the next 1 to 3 years based on estimates from 4 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
63.5%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Aurinia Pharmaceuticals expected to grow at an attractive rate?
  • Aurinia Pharmaceuticals's earnings growth is expected to exceed the low risk savings rate of 0.2%.
Growth vs Market Checks
  • Aurinia Pharmaceuticals's earnings growth is expected to exceed the Germany market average.
  • Aurinia Pharmaceuticals's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:IKAP Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:IKAP Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 4 Analysts 63.5%
DB:IKAP Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 4 Analysts 56%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 47.5%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26.1%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.8%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:IKAP Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 4 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:IKAP Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 437 166 234 2
2022-12-31 267 150 127 2
2021-12-31 110 70 67 2
2020-12-31 57 8 6 2
2019-12-31 0 -57 -62 4
DB:IKAP Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2018-12-31 0 -52 -64
2018-09-30 0 -47 -53
2018-06-30 0 -44 -48
2018-03-31 0 -46 -34
2017-12-31 0 -41 -71
2017-09-30 0 -36 -76
2017-06-30 0 -32 -70
2017-03-31 0 -23 -71
2016-12-31 0 -19 -23
2016-09-30 0 -19 -19
2016-06-30 0 -20 -17
2016-03-31 0 -19 -14

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Aurinia Pharmaceuticals's earnings are expected to grow significantly at over 20% yearly.
  • Aurinia Pharmaceuticals's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:IKAP Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 4 Analyst Estimates (S&P Global) See Below

All data from Aurinia Pharmaceuticals Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:IKAP Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 2.19 2.38 2.00 2.00
2022-12-31 1.15 1.41 1.00 3.00
2021-12-31 0.65 0.65 0.65 1.00
2020-12-31 -0.05 0.12 -0.32 3.00
2019-12-31 -0.68 -0.42 -0.87 6.00
DB:IKAP Past Financials Data
Date (Data in USD Millions) EPS *
2018-12-31 -0.76
2018-09-30 -0.63
2018-06-30 -0.56
2018-03-31 -0.41
2017-12-31 -0.92
2017-09-30 -1.15
2017-06-30 -1.30
2017-03-31 -1.71
2016-12-31 -0.66
2016-09-30 -0.57
2016-06-30 -0.52
2016-03-31 -0.44

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Aurinia Pharmaceuticals is expected to efficiently use shareholders’ funds in the future (Return on Equity greater than 20%).
X
Future performance checks
We assess Aurinia Pharmaceuticals's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Aurinia Pharmaceuticals has a total score of 6/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

IKAP Past Performance

  How has Aurinia Pharmaceuticals performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Aurinia Pharmaceuticals's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Aurinia Pharmaceuticals does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Aurinia Pharmaceuticals's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Aurinia Pharmaceuticals's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Aurinia Pharmaceuticals's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Aurinia Pharmaceuticals Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:IKAP Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 0.46 -64.12 13.67
2018-09-30 0.47 -52.86 13.81
2018-06-30 0.12 -47.64 13.54
2018-03-31 0.42 -34.33 12.98
2017-12-31 0.42 -70.79 12.10
2017-09-30 0.42 -75.79 10.69
2017-06-30 0.42 -70.09 9.75
2017-03-31 0.15 -70.97 8.69
2016-12-31 0.17 -23.30 6.97
2016-09-30 0.20 -19.03 6.31
2016-06-30 0.23 -16.82 5.97
2016-03-31 0.23 -14.27 5.55
2015-12-31 0.24 -18.61 6.26
2015-09-30 0.25 -20.90 6.10
2015-06-30 0.26 -12.95 6.12
2015-03-31 0.27 -23.25 6.42
2014-12-31 0.28 -19.42 6.89
2014-09-30 0.92 -14.76 6.31
2014-06-30 0.93 -16.72 5.40
2014-03-31 0.95 -6.65 4.18
2013-12-31 0.97 -2.66 2.30
2013-09-30 0.40 -6.01 2.38
2013-06-30 0.40 -8.29 2.79
2013-03-31 0.41 -9.86 3.34
2012-12-31 6.15 -9.72 3.89
2012-09-30 6.18 -11.20 3.76
2012-06-30 6.43 -6.95 3.35

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Aurinia Pharmaceuticals has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Aurinia Pharmaceuticals has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Aurinia Pharmaceuticals improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Aurinia Pharmaceuticals's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Aurinia Pharmaceuticals has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

IKAP Health

 How is Aurinia Pharmaceuticals's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Aurinia Pharmaceuticals's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Aurinia Pharmaceuticals is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Aurinia Pharmaceuticals's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Aurinia Pharmaceuticals's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Aurinia Pharmaceuticals has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Aurinia Pharmaceuticals Company Filings, last reported 3 months ago.

DB:IKAP Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 112.58 0.00 125.86
2018-09-30 125.34 0.00 138.88
2018-06-30 142.17 0.00 150.20
2018-03-31 152.45 0.00 159.13
2017-12-31 165.74 0.00 173.46
2017-09-30 167.64 0.00 182.41
2017-06-30 178.47 0.00 189.79
2017-03-31 172.66 0.00 202.12
2016-12-31 35.95 0.00 39.65
2016-09-30 20.10 0.00 15.38
2016-06-30 19.54 0.00 12.12
2016-03-31 16.03 0.00 10.53
2015-12-31 19.96 0.00 15.75
2015-09-30 23.54 0.00 20.58
2015-06-30 28.01 0.00 25.74
2015-03-31 27.56 0.00 29.04
2014-12-31 33.87 0.00 32.70
2014-09-30 49.32 0.00 35.53
2014-06-30 51.07 0.00 39.09
2014-03-31 54.62 0.00 43.29
2013-12-31 13.31 1.32 1.82
2013-09-30 12.26 1.70 4.51
2013-06-30 -2.89 0.02 0.45
2013-03-31 -2.92 0.03 0.03
2012-12-31 -2.11 1.74 0.18
2012-09-30 2.21 0.05 0.29
2012-06-30 3.76 0.06 1.35
  • Aurinia Pharmaceuticals has no debt.
  • Aurinia Pharmaceuticals has no debt compared to 5 years ago when it was 9.5%.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Aurinia Pharmaceuticals has sufficient cash runway for 2.4 years based on current free cash flow.
  • Aurinia Pharmaceuticals has sufficient cash runway for 2 years if free cash flow continues to grow at historical rates of 39.5% each year.
X
Financial health checks
We assess Aurinia Pharmaceuticals's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Aurinia Pharmaceuticals has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

IKAP Dividends

 What is Aurinia Pharmaceuticals's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Aurinia Pharmaceuticals dividends.
If you bought €2,000 of Aurinia Pharmaceuticals shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Aurinia Pharmaceuticals's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Aurinia Pharmaceuticals's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:IKAP Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 4 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 326 Stocks 3%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:IKAP Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31
2020-12-31
2019-12-31

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Aurinia Pharmaceuticals has not reported any payouts.
  • Unable to verify if Aurinia Pharmaceuticals's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Aurinia Pharmaceuticals's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Aurinia Pharmaceuticals has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Aurinia Pharmaceuticals's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Aurinia Pharmaceuticals afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Aurinia Pharmaceuticals has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

IKAP Management

 What is the CEO of Aurinia Pharmaceuticals's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Richard Glickman
COMPENSATION $3,192,700
AGE 60
TENURE AS CEO 2.2 years
CEO Bio

Dr. Richard M. Glickman, L.L.D. (Hon), serves as a Partner at Lumira Capital Corp. Dr. Glickman serves as a Venture Partner at Kearny Venture Partners. Dr. Glickman Co-founded Aurinia Pharmaceuticals Inc. and served as its Executive Chairman. Dr. Glickman has been President and Chief Executive Officer of Aurinia Pharmaceuticals Inc. since February 6, 2017 and also serves its Chairman. Dr. Glickman served as an Acting Chief Executive Officer of Aurinia Pharmaceuticals Inc. from October 22, 2013 to November 5, 2013. Dr. Glickman served as a Business Advisor of Valocor Therapeutics, Inc. He served as a Special Advisor of MedGenesis Therapeutix Inc. He co-founded Aspreva International Ltd. in 2001 and served as its Chairman and Chief Executive Officer from January 2002 to July 11, 2007. He was a co-founder, Chairman and Chief Executive Officer of Aspreva Pharmaceuticals. He co-founded StressGen Biotechnologies Corporation and served as its President and Chief Executive Officer until 2000. He co-founded Probtec Corporation and served as its Vice-President of Corporate Development, where Dr. Glickman established and introduced the first licensed DNA-based forensic and paternity testing services into Canada. He founded Ontario Molecular Diagnostics. Dr. Glickman has over 30 years of experience in the creation and operation of healthcare ventures, founding and co-founding numerous companies during his career. He is the Chairman of Isotechnika Pharma Inc. since September 23, 2013 and ESSA Pharma Inc. since October 2010. He serves as a Director at ESSA Pharma Inc. since October 2010. He serves as the Chairman of Vigil Health Management and Life Sciences B.C. He has been the Chairman of the Board at Aurinia Pharmaceuticals Inc. since August 2013. He serves as the Chairman of the Board of Engene Inc. He serves as a Vice-Chairman of StressGen. He served as its Executive Chairman from September 20, 2013 to February 28, 2014. He has been a Director at Correvio Pharma Corp. since December 11, 2006 and served as its Lead Independent Director since June 11, 2007 until March 2019. He is a Director of Isotechnika Pharma Inc. since August 15, 2013. He serves as a Director of British Columbia Innovation Council. He is a member of the Canadian federal government's National Biotechnology Advisory Committee. Dr. Glickman is an Executive of the Board of Directors of the Canadian Genetic Diseases Network. Dr. Glickman serves as a Director of Epic Biosonics Incorporated. He is a Member of Strategic Advisory Board at Ico Therapeutics Inc. since November 2005. He is a Non-Executive Director of enGene, Inc. since October 2011. He served as the Chairman of Vigil Health Solutions Inc., from 2000 to 2005. He served as a Director of MedGenesis Therapeutix Inc. He served as a Director of Vigil Health Solutions Inc. since April 7, 2000. He served as a Vice Chairman of Nventa Biopharmaceuticals Corporation. He served as a Director of Aspreva Pharmaceuticals Corporation from January 2002 to July 11, 2007 and served as Director at Kinexus Bioinformatics Corporation and Ontario Molecular Diagnostics. He served as Director of viDA Therapeutics Inc until June 23, 2016. Dr. Glickman has served on numerous biotechnology and community boards including roles as Chairman of Life Sciences B.C., Director of the Canadian Genetic Disease Network and as a Director for the Vancouver Aquarium. He is the recipient of both Canada's and British Columbia's Top 40 under 40 Awards for Entrepreneurs and has been the recipient of 2006 BC Biotech Leadership Award. He received the Ernst & Young Entrepreneur of the Year 2004 Award for the Pacific Region Life Sciences Group. He has a successful track record raising capital for pharmaceutical and biopharmaceutical companies. He is one of Canada’s best known and most successful healthcare entrepreneurs. Dr. Glickman holds a B.Sc. in Microbiology and Immunology from the McGill University.

CEO Compensation
  • Richard's compensation has increased whilst company is loss making.
  • Richard's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure

Average tenure of the Aurinia Pharmaceuticals management team in years:

1.8
Average Tenure
  • The average tenure for the Aurinia Pharmaceuticals management team is less than 2 years, this suggests a new team.
Management Team

Richard Glickman

TITLE
Founder
COMPENSATION
$3M
AGE
60
TENURE
2.2 yrs

Michael Martin

TITLE
Co-Founder & COO
COMPENSATION
$526K

Dennis Bourgeault

TITLE
CFO & Secretary
COMPENSATION
$681K
TENURE
20.9 yrs

Rob Huizinga

TITLE
Executive Vice President of Corporate Development
COMPENSATION
$648K
TENURE
1.9 yrs

Neil Solomons

TITLE
Chief Medical Officer
COMPENSATION
$792K
TENURE
5.6 yrs

Glenn Schulman

TITLE
Consultant and Investor Relations Officer

Erik Eglite

TITLE
Chief Compliance Officer
AGE
53
TENURE
1.8 yrs

Rivka Gluck

TITLE
Senior Vice President of Global Clinical Operations
TENURE
1.3 yrs

Simrat Randhawa

TITLE
Senior VP of Clinical & Medical Affairs
TENURE
1.7 yrs

Sue Evans

TITLE
Head of Regulatory Affairs
TENURE
1.3 yrs
Board of Directors Tenure

Average tenure and age of the Aurinia Pharmaceuticals board of directors in years:

3.8
Average Tenure
67.5
Average Age
  • The tenure for the Aurinia Pharmaceuticals board of directors is about average.
Board of Directors

Richard Glickman

TITLE
Founder
COMPENSATION
$3M
AGE
60
TENURE
5.7 yrs

Beni Rovinski

TITLE
Director
COMPENSATION
$160K
AGE
61
TENURE
5.6 yrs

Jeff Randall

TITLE
Lead Director
COMPENSATION
$191K
AGE
74
TENURE
1.8 yrs

George Milne

TITLE
Director
COMPENSATION
$239K
AGE
74
TENURE
1.9 yrs

Norman Kneteman

TITLE
Member of Scientific Advisory Board

Walter Maksymowych

TITLE
Member of Scientific Advisory Board

Anthony Jevnikar

TITLE
Member of Transplant Advisory Board & Scientific Advisory Board

Neil Shear

TITLE
Member of the Clinical Advisory Board

Kim Papp

TITLE
Member of the Scientific Advisory Board & Clinical Advisory Board

Richard Lewanczuk

TITLE
Member of the Scientific Advisory Board
Who owns this company?
Recent Insider Trading
  • Aurinia Pharmaceuticals insiders have sold more shares than they have bought in the past 3 months.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
08. Apr 19 Buy ILJIN SNT Co., Ltd Company 14. Feb 19 14. Feb 19 145,533 €2.86 €415,667
05. Apr 19 Sell Neil Solomons Individual 03. Apr 19 03. Apr 19 -10,000 €6.07 €-60,681
04. Mar 19 Sell Neil Solomons Individual 27. Feb 19 01. Mar 19 -150,700 €6.27 €-912,715
08. Feb 19 Sell Neil Solomons Individual 04. Feb 19 04. Feb 19 -10,000 €5.81 €-58,094
31. Jan 19 Sell Neil Solomons Individual 28. Jan 19 29. Jan 19 -10,000 €5.47 €-53,568
29. Jan 19 Buy Richard Glickman Individual 29. Jan 19 29. Jan 19 8,000 €5.34 €42,732
18. Jan 19 Sell Robert Duggan Individual 04. Dec 18 16. Jan 19 -562,419 €6.76 €-3,224,217
11. Jan 19 Sell Michael Martin Individual 07. Jan 19 09. Jan 19 -24,798 €6.24 €-153,214
07. Jan 19 Sell Michael Martin Individual 02. Jan 19 02. Jan 19 -25,000 €6.04 €-151,025
03. Jan 19 Sell Vassiliki Economides Individual 28. Dec 18 28. Dec 18 -220 €5.78 €-1,272
27. Dec 18 Sell Neil Solomons Individual 24. Dec 18 24. Dec 18 -3,500 €4.83 €-16,915
18. Dec 18 Buy Dennis Bourgeault Individual 18. Dec 18 18. Dec 18 1,000 €5.00 €4,997
19. Nov 18 Sell Neil Solomons Individual 13. Nov 18 15. Nov 18 -36,600 €4.68 €-171,038
15. Oct 18 Sell Rashieda Gluck Individual 11. Oct 18 11. Oct 18 -6,100 €4.94 €-30,108
20. Jun 18 Buy Rashieda Gluck Individual 18. Jun 18 18. Jun 18 700 €5.13 €3,592
12. Jun 18 Buy Rashieda Gluck Individual 07. Jun 18 07. Jun 18 1,483 €2.34 €3,474
12. Jun 18 Buy Rashieda Gluck Individual 07. Jun 18 07. Jun 18 3,800 €4.82 €18,318
X
Management checks
We assess Aurinia Pharmaceuticals's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Aurinia Pharmaceuticals has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

IKAP News

Simply Wall St News

IKAP Company Info

Description

Aurinia Pharmaceuticals Inc., a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutic drugs for the treatment of various diseases in the United States and China. The company is involved in developing voclosporin, an investigational drug for the treatment of lupus nephritis, dry eye syndrome, and focal segmental glomerulosclerosis. Aurinia Pharmaceuticals Inc. is headquartered in Victoria, Canada.

Details
Name: Aurinia Pharmaceuticals Inc.
IKAP
Exchange: DB
Founded:
CA$515,781,459
91,636,000
Website: http://www.auriniapharma.com
Address: Aurinia Pharmaceuticals Inc.
4464 Markham Street,
Suite 1203,
Victoria,
British Columbia, V8Z 7X8,
Canada
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
TSX AUP Common Shares The Toronto Stock Exchange CA CAD 26. Jan 1999
NasdaqGM AUPH Common Shares Nasdaq Global Market US USD 26. Jan 1999
DB IKAP Common Shares Deutsche Boerse AG DE EUR 26. Jan 1999
LSE 0UJF Common Shares London Stock Exchange GB CAD 26. Jan 1999
Number of employees
Current staff
Staff numbers
39
Aurinia Pharmaceuticals employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/25 21:52
End of day share price update: 2019/04/25 00:00
Last estimates confirmation: 2019/04/12
Last earnings filing: 2019/03/19
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.